Get the Stockscreener App
70.24
1.89%
1.2815
Tarsus Pharmaceuticals Inc stock is traded at $70.24, with a volume of 130.09K.
It is up +1.89% in the last 24 hours and up +18.22% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$68.96
Open:
$68.72
24h Volume:
130.09K
Relative Volume:
0.20
Market Cap:
$2.96B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-15.14
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+6.36%
1M Performance:
+18.22%
6M Performance:
+35.35%
1Y Performance:
+57.92%
1-Day Range:
$68.69
$70.84
1-Week Range:
$65.99
$70.84
52-Week Range:
$38.51
$76.81
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
70.22 | 2.91B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.79 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
655.88 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.12 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
812.69 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.06 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals (TARS) to Release Earnings on Tuesday - MarketBeat
What to expect from Tarsus Pharmaceuticals Inc. in the next 30 days2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
How analysts rate Tarsus Pharmaceuticals Inc. stock todayTrade Signal Summary & Low Risk Entry Point Guides - newser.com
What’s the recovery path for long term holders of Tarsus Pharmaceuticals Inc.2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Can Tarsus Pharmaceuticals Inc. recover in the next quarterPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Top chart patterns to watch in Tarsus Pharmaceuticals Inc.CEO Change & Low Risk High Win Rate Stock Picks - newser.com
Jennison Associates LLC Trims Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Applying sector rotation models to Tarsus Pharmaceuticals Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Will Tarsus Pharmaceuticals Inc. stock deliver shareholder value2025 Market Overview & Weekly High Return Opportunities - newser.com
Is Tarsus Pharmaceuticals Inc. stock poised for growth2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
Forecasting Tarsus Pharmaceuticals Inc. price range with options dataIndex Update & Weekly High Momentum Picks - newser.com
Is Tarsus Pharmaceuticals Inc. stock a safe investment in uncertain marketsTrade Risk Summary & Step-by-Step Swing Trade Plans - newser.com
Is Tarsus Pharmaceuticals Inc. stock cheap at current valuation2025 Price Action Summary & Reliable Entry Point Trade Alerts - newser.com
Is Tarsus Pharmaceuticals Inc. showing signs of accumulation2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - newser.com
Full technical analysis of Tarsus Pharmaceuticals Inc. stockWeekly Investment Report & Verified Momentum Watchlists - newser.com
Tarsus Pharmaceuticals, Inc. to Host Live Webcast for Q3 2025 Financial Results and Corporate Update - Quiver Quantitative
Tarsus (NASDAQ: TARS) sets Nov. 4 webcast to share third‑quarter results at 1:30 p.m. PT - Stock Titan
Can Tarsus Pharmaceuticals Inc. stock sustain market leadershipPortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Is Tarsus Pharmaceuticals Inc. stock attractive for long term wealth building2025 Dividend Review & Technical Entry and Exit Tips - Fundação Cultural do Pará
How Tarsus Pharmaceuticals Inc. stock performs in weak economy2025 Performance Recap & Daily Entry Point Trade Alerts - Fundação Cultural do Pará
Does Tarsus Pharmaceuticals Inc. qualify in momentum factor screening2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Will Tarsus Pharmaceuticals Inc. stock gain from strong economyJuly 2025 Volume & Low Risk Entry Point Tips - Fundação Cultural do Pará
Can Tarsus Pharmaceuticals Inc. stock resist market sell offsSell Signal & Smart Allocation Stock Tips - newser.com
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase - The Motley Fool
Tarsus Pharmaceuticals Inc. stock trend outlook and recovery pathWeekly Trend Report & Capital Efficiency Focused Strategies - newser.com
AlphaQuest LLC Has $836,000 Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):